BLA 761269 · Eisai INC
Leqembi
Lecanemab-Irmb · Injection · Amyloid Beta-directed Antibody
NovelBreakthrough therapyAccelerated approvalPriority reviewCDER novel approval, Jan 6, 2023: To treat Alzheimer's disease
Last checked: Nov 20, 2026Latest source record: Jan 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Jan 6, 2023
Approved uses
3
Original approval plus efficacy supplements
Registered trials
19
6 Phase 3, 6 recruiting
FAERS reports
3,813
1,660 serious, 164 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: AMYLOID RELATED IMAGING ABNORMALITIES Monoclonal antibodies directed against aggregated forms of beta amyloid, including LEQEMBI, can cause amyloid related imaging abnormalities (ARIA), characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events can occur. ARIA can be fatal. Serious intracerebral hemorrhage s > 1 cm, some of which have been fatal, have been observed in patients treated with this class of medications. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, treating clinicians should consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy to a patient being treated with LEQEMBI [see Warnings and Precautions (...
What it is approved for
From the label in effect Jul 21, 2026.
LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. LEQEMBI is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. ( 1 )
Mechanism: Lecanemab-irmb is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer’s disease. LEQEMBI reduces amyloid beta plaques, as evaluated in Study 1 and Study 2 [see Clinical Studies ( 14 )] .
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 24, 2025 Supplement 5 · Efficacy LabelLetter
- Jul 6, 2023 Supplement 1 · Efficacy · priority review LabelLetterReview
- Jan 6, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLetterSummary ReviewLabel
2 products under this application
- LEQEMBI · LECANEMAB-IRMB 200MG/2ML · INJECTABLE, INJECTION · Prescription
- LEQEMBI · LECANEMAB-IRMB 500MG/5ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lecanemab" as an intervention, any sponsor and status, largest first.
- A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseasePivotal-lookingActive, not recruiting
Eisai Inc.Eisai
NCT03887455 · 1,906 participants · Start Mar 27, 2019 · Primary completion Dec 31, 2026
Drug: Lecanemab IV; Placebo and 1 more · For: Early Alzheimer's Disease
Sites: Phoenix, Arizona; Sun City, Arizona; Tucson, Arizona · 247 sites in all
- AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate AmyloidPivotal-lookingActive, not recruiting
Eisai Inc.Eisai
NCT04468659 · 1,400 participants (planned) · Start Jul 14, 2020 · Primary completion Dec 21, 2028
Drug: Lecanemab; Placebo · For: Preclinical Alzheimer's Disease; Early Preclinical Alzheimer's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Sun City, Arizona · 107 sites in all
- A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's DiseasePivotal-lookingCompleted
Eisai Inc.Eisai
NCT01767311 · 856 participants · Start Dec 20, 2012 · Primary completion Dec 10, 2024
Drug: Lecanemab 2.5 mg/kg; Lecanemab 5.0 mg/kg and 5 more · For: Alzheimer's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 169 sites in all
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001Pivotal-lookingActive, not recruiting
Washington University School of MedicineAcademic, hospital or other
NCT01760005 · 490 participants (planned) · Start Dec 2012 · Primary completion Apr 2028
Drug: Gantenerumab; Solanezumab and 6 more · For: Alzheimers Disease; Dementia; Alzheimers Disease, Familial
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 38 sites in all
- Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics ApproachsPivotal-lookingRecruiting
First Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT07604896 · 200 participants (planned) · Start Jan 1, 2026 · Primary completion Dec 31, 2027
Drug: Lecanemab 10 mg/kg; Conventional anti-dementia treatment group · For: Alzheimer s Disease; Alzheimer Dementia (AD); MCI-AD, Early Stage Alzheimer's Disease
Sites: Wenzhou, China
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)Pivotal-lookingActive, not recruiting
Washington University School of MedicineAcademic, hospital or other
NCT05269394 · 197 participants · Start Dec 22, 2021 · Primary completion Apr 2028
Drug: E2814; Lecanemab and 1 more · For: Alzheimers Disease; Dementia; Alzheimers Disease, Familial
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 31 sites in all
- A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy ParticipantsPivotal-lookingCompleted
Eisai Inc.Eisai
NCT05533801 · 160 participants · Start Sep 6, 2022 · Primary completion Jan 6, 2023
Drug: Lecanemab; Lecanemab · For: Healthy Volunteers
Sites: Anaheim, California
- A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's DiseasePivotal-lookingActive, not recruiting
Eisai Inc.Eisai
NCT06602258 · 105 participants · Start Sep 30, 2024 · Primary completion Dec 3, 2026
Drug: E2814; Lecanemab and 1 more · For: Alzheimer's Disease
Sites: Phoenix, Arizona; New Haven, Connecticut; Bradenton, Florida · 26 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- amyloid related imaging abnormality-oedema/effusion530
- headache492
- amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits487
- infusion related reaction330
- chills249
- fatigue225
- pyrexia179
- dizziness175
- confusional state172
- nausea156
- cerebral haemorrhage136
- fall118
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2022 | 7 |
| 2023 | 263 |
| 2024 | 1,402 |
| 2025 | 1,364 |
| 2026 | 776 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Leqembi (Lecanemab-Irmb)
2024 spending
$514K
Beneficiaries
48
399 claims
Per beneficiary
$10,714
$136.81 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $17,321 |
| 2024 | $514,268 |
Part B: Leqembi (Lecanemab-Irmb) · HCPCS J0174
2024 spending
$90.4M
Beneficiaries
7,907
86,149 claims
Per beneficiary
$11,429
2024 ASP limit $1.34 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $4,243,344 |
| 2024 | $90,371,611 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Lecanemab in Early Alzheimer's Disease.
van Dyck CH, Swanson CJ, Aisen P, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Multicenter Study
- Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
Honig LS, Sabbagh MN, van Dyck CH, et al. · Alzheimers Res Ther 2024 · Multicenter Study, Randomized Controlled Trial
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Swanson CJ, Zhang Y, Dhadda S, et al. · Alzheimers Res Ther 2021 · Clinical Trial, Phase II, Randomized Controlled Trial
- Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.
Terao I, Kodama W · Ageing Res Rev 2024 · Comparative Study, Systematic Review
- Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open-label extension study.
van Dyck CH, Sperling R, Johnson K, et al. · Alzheimers Dement 2025 · Randomized Controlled Trial
- The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
Wu W, Ji Y, Wang Z, et al. · Eur J Med Res 2023 · Meta-Analysis, Systematic Review
Sponsor: Eisai
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.